Company profile: Innocoll
1.1 - Company Overview
Company description
- Provider of targeted drug delivery solutions focused on biodegradable surgical implants and topically applied healthcare products, including XARACOLL, a resorbable collagen implant with bupivacaine for pain relief up to 24 hours after open inguinal hernia repair; POSIMIR, a single‑site bupivacaine injection providing relief up to 72 hours after arthroscopic subacromial decompression; the COLLARx collagen matrix platform; and CDMO services.
Products and services
- XARACOLL: A fully resorbable and biodegradable collagen implant containing bupivacaine, engineered to deliver immediate and long-lasting analgesia for up to 24 hours after adult open inguinal hernia repair
- COLLARx: A platform that produces a lyophilized porous matrix of purified collagen, enabling precise control over drug elution dynamics, texture, consistency, and resorption time
- POSIMIR: A locally administered, single-site bupivacaine injection that delivers significant postoperative pain relief for up to 72 hours following arthroscopic subacromial decompression
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Innocoll
NuGen Medical Devices
HQ: Canada
Website
- Description: Provider of needle-free medical delivery technologies, including InsuJet, a spring-loaded injection system for self-administration by patients and healthcare practitioners that delivers drugs through the skin, and PetJet, a device for veterinary use facilitating painless, quick treatment for pets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NuGen Medical Devices company profile →
BlueWillow Biologics
HQ: United States
Website
- Description: Provider of intranasal vaccine and adjuvant technologies, including an oil-in-water emulsion Intranasal Adjuvant Technology, NE01 adjuvanted intranasal vaccines, the BW-1010 anthrax vaccine candidate, and a therapeutic peanut allergy vaccine, built on the NanoVax platform to elicit mucosal, cellular, and systemic immunity; also focused on topical antiseptic and anti-infective products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BlueWillow Biologics company profile →
Elektrofi
HQ: United States
Website
- Description: Provider of a microparticle platform (Hypercon) enabling low-volume, stable, hyper-concentrated biologic formulations for subcutaneous delivery, alongside formulation development services—covering process development, formulation, analytics, and innovation—and partnership programs with pharmaceutical companies to develop and commercialize subcutaneous biologic therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elektrofi company profile →
Cellectar Biosciences
HQ: United States
Website
- Description: Provider of radiopharmaceutical cancer therapies and diagnostics, designing phospholipid drug conjugates that target tumor cells to detect, treat, and monitor cancers. Lead candidate iopofosine I 131 is in Phase 2/1 studies. Pipeline includes CLR 1900 cytotoxic compounds and collaborative PDC programs (CLR 2000, CLR 12120) with Avicenna and Orano Med, plus new PDCs with IntoCell and LegoChemBio.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellectar Biosciences company profile →
Mercator MedSystems
HQ: United States
Website
- Description: Provider of site-specific delivery devices for the treatment of vascular, oncologic, and regenerative diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mercator MedSystems company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Innocoll
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Innocoll
2.2 - Growth funds investing in similar companies to Innocoll
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Innocoll
4.2 - Public trading comparable groups for Innocoll
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →